Genmab GMAB shares are trading lower on Wednesday after the company announced legal arbitration with partner Johnson & Johnson JNJ over Darzalex royalty payments.
Genmab is a Copenhagen-based cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
Genmab shares were trading down 8.8% at $34.84 on Wednesday. The stock has a 52-week high of $38.87 and a 52-week low of $16.24.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
